ScreenerHero

NRXS NeurAxis, Inc.

AMEX · US · Healthcare · Biotechnology · neuraxis.com
6.830USD+0.74%Mkt Cap: 85.77M $P/E: —

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap85.77M USD
Enterprise Value77.10M USD
Revenue (TTM)5.32M USD
Gross Profit3.01M USD
Net Income (TTM)-7.80M USD
Revenue/Share0.49 USD
Last Price6.830 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-25.11
PEG—
EV/EBITDA-10.13
EV/Revenue14.50
P/S16.02
P/B12.56
EPS (TTM)-0.78
EPS (Forward)-0.27
52W Range
2.21065% of range9.330
52W High9.330 USD
52W Low2.210 USD
Profitability
Gross Margin84.23%
Oper. Margin-110.16%
EBITDA Margin-143.13%
Profit Margin-218.55%
ROE-229.47%
ROA-121.81%
Growth
Revenue Growth115.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.43M USD
CapEx (TTM)131.15K USD
FCF Margin-59.35%
FCF Yield-3.68%
Net Debt-8.04M USD
Net Debt/EBITDA1.06
Balance Sheet
Debt/Equity0.12
Current Ratio3.04
Quick Ratio2.83
Book Value/Sh0.54 USD
Cash/Share0.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Upside (mean)+61.1%
Target Range9.000 USD – 13.00 USD
9.000+61.1% to mean13.00
# Analysts2
Ownership
Shares Out.12.56M
Float8.34M
Insiders25.34%
Institutions28.44%
Short Interest
Short Ratio5.5d
Short % Float3.84%
Short % Out.3.00%
Shares Short377.07K
Short (prev mo.)410.75K
Technical
SMA 506.546 (+4.3%)
SMA 2006.374 (+7.1%)
Beta1.36
S&P 52W Chg15.77%
Avg Vol (30d)115.25K
Avg Vol (10d)95.33K
Technical Indicators
RSI (14)48.8
MACD0.1646
MACD Signal0.2187
MACD Hist.-0.0541
BB Upper8.410 USD
BB Middle6.923 USD
BB Lower5.436 USD
BB Width42.97%
ATR (14)0.5106 USD
Vol Ratio (20d)0.47x